Yinuo Pharmaceutical, which developed the first specific drug for atherosclerosis to enter clinical trials; Yimei Shenzhou, which obtained the first “Drug Production License” for CART cell treatment in Beijing; formed the world's first large-scale stem cell amplification process based on 3D cell microcarriers... Up to now, the Zhongguancun Qianqian Incubation Innovation Center has cultivated more than 30 incubated companies. The concentration of the medical and health industry has exceeded 95%. Revenue has grown from less than 100 million yuan to over 600 million yuan, with a compound annual growth rate of over 100%. Over 50 million yuan.

Yinuo Pharmaceutical, which developed the first specific drug for atherosclerosis to enter clinical trials; Yimei Shenzhou, which obtained the first “Drug Production License” for CART cell treatment in Beijing; formed the world's first large-scale stem cell amplification process based on 3D cell microcarriers... Up to now, the Zhongguancun Qianqian Incubation Innovation Center has cultivated more than 30 incubated companies. The concentration of the medical and health industry has exceeded 95%. Revenue has grown from less than 100 million yuan to over 600 million yuan, with a compound annual growth rate of over 100%. Over 50 million yuan.